|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Of these potential substrates, serine 418 of the tumor suppressor CYLD was identified as a likely site of IKKepsilon phosphorylation.
|
19481526 |
2009 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Phenotype variability in tumor disorders of the skin appendages associated with mutations in the CYLD gene.
|
29974194 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In this manuscript we report that the tumor suppressor CYLD, similarly to other renowned tumor suppressor genes, protects from premature aging and cancer.
|
30631004 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
These include deletion of the tumor suppressor CYLD, promotor methylation of the Wnt antagonists WIF1, DKK1, DKK3, and sFRP1, sFRP2, sFRP4, sFRP5, as well as overexpression of the co-transcriptional activator BCL9 and the R-spondin receptor LGR4.
|
30770859 |
2019 |
|
Neoplasms
|
0.200 |
AlteredExpression
|
group |
BEFREE |
Thus, functional relevant loss of CYLD expression may contribute to tumor development and progression, and may provide a new target for therapeutic strategies.
|
16774947 |
2007 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction.
|
19917957 |
2009 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
This observation suggests that the cyld1 gene may be the only tumour suppressor gene implicated in the development of cylindromas.
|
8649842 |
1996 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Patients with germline mutations in a tumour suppressor gene called CYLD develop multiple, disfiguring, hair follicle tumours on the head and neck.
|
28270164 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD lysine 63 deubiquitinase (CYLD) was originally identified as a tumor suppressor that is mutated in familial cylindromatosis.
|
29344161 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
To elucidate how CYLD contributes to tumor formation, we aimed to identify molecular partners in keratinocytes.
|
31260673 |
2020 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The loss of CYLD gene of tumor suppressor gene, 16q12-q13, was only on locus of common involvement in 3 cell lines.
|
18799932 |
2008 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
For this, we explored the tumor microenvironment for targeted drug delivery and synthesized (temperature and pH responsive) double triggered polymeric nanoparticles by the free radical mechanism and characterized them by DLS and TEM.
|
31549130 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
In addition, we delineate how CYLD interferes with activation of the proto-oncogene Bcl(3) and with cyclin D1 expression to limit tumorigenesis, and chart how tumor growth-promoting agents or UV light and inflammatory mediators can activate CYLD.
|
18008375 |
2007 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
More importantly, the PfL treatment leads to effective inhibition of tumor growth and a ∼2.71 fold increase in the lifespan of EAC mice.
|
31431259 |
2019 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
PfLP treatment resulted in tumor growth inhibition and increased the life-span of the EAC bearing mice, without showing any detectable side effects, as revealed by histological parameters.
|
29174033 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Interestingly, TEM images of tumor sections show intercellular lysosomal subcellular localization of the GNP-ABPs.
|
30148621 |
2018 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Since loss of CYLD expression can be observed in different types of human cancer, it is now well established that CYLD acts as a tumor suppressor gene.
|
21345146 |
2011 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Pathogenic truncations of the CYLD C terminus, associated with the hypertrophic skin tumor cylindromatosis, disrupt the USP domain, accounting for loss of CYLD catalytic activity.
|
18313383 |
2008 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD is a deubiquitinating enzyme that exerts a tumor suppressive function.
|
27570065 |
2016 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
However, the functional consequence of CYLD loss and the mechanism underlying its putative role as a tumor suppressor gene in the pathogenesis of MM has not been established.
|
27775078 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In affected families, mutations have been demonstrated in the CYLD gene located on chromosome 16q12-13 and reveal the characteristic attributes of a tumor suppressor.
|
12190880 |
2002 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
Tumor suppressor CYLD: negative regulation of NF-kappaB signaling and more.
|
18193168 |
2008 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
CYLD is a tumor suppressor and a deubiquitination enzyme.
|
28840581 |
2017 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
More specifically, our results highlight STAT6 as a potential transcriptional target and identified RGMA, CHD2 and CYLD as candidate tumor suppressors in cHL.
|
17606441 |
2007 |
|
Neoplasms
|
0.200 |
Biomarker
|
group |
BEFREE |
The tumor suppressor CYLD is a deubiquitinating enzyme that suppresses polyubiquitin-dependent signaling pathways, including the proinflammatory and cell growth-promoting NF-κB pathway.
|
31366726 |
2019 |